Sorafenib alone vs. sorafenib plus GEMOX as 1-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial.

Authors:
Eric Assenat
Eric Assenat
Department of Clinical Nutrition and Gastroenterology
Gainesville | United States
Simon Thezenas
Simon Thezenas
Val d'Aurelle Cancer Institute
France
Jean-Marie Peron
Jean-Marie Peron
Université Paul Sabatier
France
Yves Becouarn
Yves Becouarn
Clinical and Epidemiological Research Unit
Philippe Merle
Philippe Merle
University of Sussex
United Kingdom

Br J Cancer 2019 Apr 4;120(9):896-902. Epub 2019 Apr 4.

Gustave Roussy, Villejuif, France.

Background: Sorafenib remains one major first-line therapeutic options for advanced hepatocellular carcinoma (aHCC), with modest efficacy. We investigated the addition of gemcitabine and oxaliplatin (GEMOX) to sorafenib in aHCC patients.

Methods: Our multicentre phase II trial randomised aHCC first-line patients to sorafenib (400 mg BID) or sorafenib-GEMOX every 2 weeks (1000 mg/m gemcitabine; 100 mg/m oxaliplatin). Primary endpoint was the 4-month progression-free survival (PFS) rate.

Results: Ninety-four patients were randomised (sorafenib-GEMOX: n = 48; sorafenib: n = 46). Median age was 64 years, PS 0 (69%) or 1 (31%), 63% patients had cirrhosis, 29% portal vein thrombosis and 70% extra-hepatic disease. Median duration of sorafenib treatment was 4 months (1-51); median number of GEMOX cycles was 7 (1-16). The 4-month PFS rates were 64% and 61% in the sorafenib-GEMOX and sorafenib arms, respectively; median PFS and OS were 6.2 (95% CI: 3.8-6.8) and 13.5 (7.5-16.2) months, and 4.6 (3.9-6.2) months and 14.8 (12.2-22.2), respectively. The ORR/DCR were 9%/70% and 15%/77% in the sorafenib-GEMOX and sorafenib alone arms, respectively. Main toxicities were (sorafenib-GEMOX/sorafenib) neutropenia (23%/0), thrombocytopenia (33%/0), diarrhoea (18%/9), peripheral neuropathy (5%/0) and hand-foot syndrome (5%/18).

Conclusions: Addition of GEMOX had an inpact on ORR and was well-tolerated as frontline systemic therapy. The benefit on PFS seems moderate; no subsequent study was planned.

Download full-text PDF

Source
http://www.nature.com/articles/s41416-019-0443-4
Publisher Site
http://dx.doi.org/10.1038/s41416-019-0443-4DOI Listing
April 2019
8 Reads

Article Mentions


Provided by Crossref Event Data
twitter
Twitter:
April 6, 2019, 3:13 am EST
twitter
Twitter:
April 4, 2019, 12:24 pm EST

Publication Analysis

Top Keywords

sorafenib arms
8
sorafenib
8
sorafenib-gemox sorafenib
8
sorafenib treatment
4
treatment months
4
months 1-51
4
duration sorafenib
4
disease median
4
extra-hepatic disease
4
1-51 median
4
70% extra-hepatic
4
median duration
4
median number
4
pfs rates
4
rates 64%
4
64% 61%
4
61% sorafenib-gemox
4
4-month pfs
4
1-16 4-month
4
number gemox
4

Similar Publications